Table 4. Stratified analysis of LMP2 gene codon 60 genotypes with chronic HCV infection.

Stratified characteristics	Persistent infection [n (%)]		Spontaneous clearance [n (%)]		Controls [n (%)]		Controls/Persistent infection OR(95%CI)*		Controls/Spontaneous clearance OR(95%CI)*		Persistent infection/Spontaneous clearance OR(95%CI)*
	Arg/Arg	Arg/His +His/His	Arg/Arg	Arg/His +His/His	Arg/Arg	Arg/His +His/His	Arg/Arg	Arg/His +His/His	Arg/Arg	Arg/His +His/His	Arg/Arg	Arg/His +His/His
Age (y)
≤30	38(67.9)	18(32.1)	52(63.4)	30(36.6)	63(60.0)	42(40.0)	1.00	0.83(0.38-1.82)	1.00	1.15(0.56-2.36)	1.00	0.81(0.39-1.68)
>30	74(63.2)	43(36.8)	61(57.0)	46(43.0)	77(64.2)	43(35.8)	1.00	0.83(0.45-1.54)	1.00	0.97(0.51-1.85)	1.00	0.73(0.42-1.26)
Gender
male	79(64.2)	44(35.8)	76(60.3)	50(39.7)	95(60.5)	62(39.5)	1.00	0.87(0.49-1.55)	1.00	0.90(0.50-1.60)	1.00	0.80(0.47-1.35)
female	33(66.0)	17(34.0)	37(58.7)	26(41.3)	45(66.2)	23(33.8)	1.00	0.65(0.26-1.62)	1.00	1.25(0.53-2.97)	1.00	0.67(0.30-1.49)
IDU
yes	91(66.4)	46(33.6)	95(59.0)	66(41.0)	42(57.5)	31(42.5)	1.00	0.68(0.37-1.26)	1.00	1.04(0.59-1.84)	1.00	0.67(0.41-1.09)
no	21(58.3)	15(41.7)	18(54.3)	10(35.7)	98(64.5)	54(35.5)	1.00	1.09(0.50-2.37)	1.00	0.91(0.38-2.16)	1.00	1.24(0.43-3.59)
Duration of drug use (y)
≤5	48(81.4)	11(18.6)	46(59.7)	31(40.3)	95(61.3)	60(38.7)	1.00	0.25(0.11-0.59)	1.00	0.74(0.38-1.46)	1.00	0.35(0.16-0.78)
5∼10	32(54.2)	27(45.8)	53(66.2)	27(33.8)	26(59.1)	18(40.9)	1.00	1.52(0.63-3.66)	1.00	0.84(0.35-2.00)	1.00	1.73(0.82-3.64)
≥10	32(58.2)	23(41.8)	14(43.8)	18(56.2)	19(73.1)	7(26.9)	1.00	2.26(0.76-6.76)	1.00	2.76(0.81-9.39)	1.00	0.54(0.22-1.34)

* Logistic regression model, adjusted by gender, age, injection drug user, and duration of drug use.